A recent study suggests that people who stop using popular slimming jabs like semaglutide or tirzepatide may regain lost weight at a significantly accelerated pace than those who end traditional diet and exercise programs.
Research printed in a major health publication shows that while overweight people frequently drop substantial amounts of their body weight while undergoing treatment, the weight returns at an estimated rate of 0.8 kg per month once they quit.
"People using these medications should be cognizant of the risk of rapid weight regain when the medication concludes," warns researcher Dr. Susan Jebb.
This pace of recovery means a return to pre-treatment weight in about one and a half years.
Comparing Approaches
The analysis, which reviewed 37 of studies involving thousands of patients, contrasted the results of GLP-1 agonists with conventional dieting.
The team emphasize that people who shed pounds through diet and exercise typically experience a less rapid creep back—approximately 0.1 kg a month—after stopping.
The Reason for the Quick Rebound
Nutrition scientists believe the way of the injections explains the amplified weight return.
GLP-1 drugs imitate a body's own chemical called GLP-1, which moderates hunger.
"Sustained high doses of GLP-1 concentrations far above than the body's typical production may cause the body to produce less of its endogenous GLP-1, and could reduce responsiveness to its effects," noted Dr. Adam Collins, a dietetics expert.
"Withdrawal of this medication means appetite is unsuppressed, making binge eating much more probable."
A Lifelong Condition?
Health authorities suggest the injections for individuals with obesity-related health risks, accompanied by prescribed lifestyle changes.
A number of clinicians argue that, given the significant potential of weight regain, the treatment is often ongoing.
This opinion is supported by pharmaceutical companies, who say that the findings "underscore the persistent character of obesity," akin to managing diseases like diabetes.
User Testimonies
Individuals who have stopped the jabs report a powerful resurgence of cravings.
"It felt as if a switch activating and you become starving," described an individual.
This challenge is exacerbated if patients have not adopted permanent dietary or behavioural modifications during therapy.
Widespread Adoption
Survey data suggest that a significant number of adults in the UK have tried these injections in the last 12 months, with interest remaining high.
- Use is more common among women compared to men.
- The middle-aged demographic shows the greatest level of interest.
- A large proportion obtain the drugs through private prescriptions rather than the NHS.
In conclusion, clinicians caution that while these medications are potent agents for weight loss, they are not a standalone solution and lasting health benefits relies on integrated behavioural support.
